| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| H0038 |
Self-help/peer services, per 15 minutes |
64,277 |
5,663 |
$9.79M |
| T1016 |
Case management, each 15 minutes |
14,574 |
1,580 |
$2.52M |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
12,049 |
4,960 |
$1.84M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
16,031 |
6,448 |
$881K |
| H2035 |
Alcohol and/or other drug treatment program, per hour |
3,468 |
239 |
$613K |
| H0015 |
Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education |
2,940 |
252 |
$390K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
3,978 |
1,308 |
$290K |
| T1017 |
Targeted case management, each 15 minutes |
749 |
89 |
$116K |
| T1023 |
Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter |
464 |
456 |
$104K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,567 |
1,388 |
$94K |
| 99215 |
Prolong outpt/office vis |
963 |
693 |
$59K |
| 99443 |
|
147 |
144 |
$5K |
| 99205 |
Prolong outpt/office vis |
16 |
13 |
$2K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
17 |
17 |
$1K |
| 96127 |
|
62 |
47 |
$101.33 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
14 |
14 |
$41.37 |